GlassScriptPhysician profile
William B Davies
NPI 1336136985
$813.69
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $117 · 2022: $16.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $202.22 | 2019-2020 | |
| Davol INC. | $158.06 | 2019-2020 | |
| Lemaitre Vascular, INC. | $93.28 | 2019 | |
| Ethicon US, LLC | $77.75 | 2019 | |
| Abbvie INC. | $74.87 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $56.19 | 2019 | |
| Tela Bio, INC. | $48.09 | 2019-2020 | |
| Csl Behring | $26.87 | 2019 | |
| Merck Sharp & Dohme LLC | $26.05 | 2019 | |
| Integra Lifesciences Corporation | $22.69 | 2019 | |
| Axonics, INC. | $15.46 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Davies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.